Exelixis
EXEL
#1602
Rank
C$14.12 B
Marketcap
$50.47
Share price
-3.32%
Change (1 day)
57.55%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2023 (TTM): $0.38

According to Exelixis's latest financial reports the company's current EPS (TTM) is $0.40. In 2022 the company made an earnings per share (EPS) of $0.81 a decrease over its 2021 EPS that were of $1.05.

EPS history for Exelixis from 2000 to 2023

Annual EPS

Year EPS Change
2023 (TTM)$0.38-53.67%
2022$0.81-22.97%
2021$1.05100%
2020$0.53-65.09%
2019$1.51-53.91%
2018$3.27333.96%
2017$0.75-260.61%
2016-$0.47-58.75%
2015-$1.14-42.45%
2014-$1.985.3%
2013-$1.8843.48%
2012-$1.31-264.29%
2011$0.80-165.88%
2010-$1.21-32.54%
2009-$1.79-17.65%
2008-$2.1875.86%
2007-$1.24-25.64%
2006-$1.678.33%
2005-$1.54-42.86%
2004-$2.6930.34%
2003-$2.06-5.23%
2002-$2.18-0.65%
2001-$2.19-51.88%
2000-$4.55

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
$4.98 1,135.69%๐Ÿ‡ฌ๐Ÿ‡ง UK
$4.53 1,022.57%๐Ÿ‡ซ๐Ÿ‡ท France
$2.59 543.02%๐Ÿ‡บ๐Ÿ‡ธ USA
$5.65 1,301.34%๐Ÿ‡บ๐Ÿ‡ธ USA
$20.14 4,894.71%๐Ÿ‡บ๐Ÿ‡ธ USA
$20.05 4,871.87%๐Ÿ‡บ๐Ÿ‡ธ USA
$2.65 556.55%๐Ÿ‡บ๐Ÿ‡ธ USA
-$14.23-3,629.83%๐Ÿ‡บ๐Ÿ‡ธ USA
-$1.20-396.51%๐Ÿ‡บ๐Ÿ‡ธ USA